DNAPrint Genomics, Inc. (OTCPK: DNAG)
Health Care · Biotechnology · US
$—
— today · — 1Y
DNAPrint Genomics, Inc. (OTCPK: DNAG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.29K and employs 24 people.
trading between 0.00 and 0.00.
Tweenvest scores DNAPrint Genomics, Inc. across four factors: value 50/100. Its strongest factor is value.
DNAG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.29K
- Revenue (TTM)
- $1.93M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 81.14
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.29B
- Employees
- 24
- Next earnings
- —
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. focuses on pioneering and distributing genetic analysis solutions and services. Their product portfolio includes AncestryByDNA, a comprehensive chromosomal assay for tracing genetic lineage, and EurasianDNA, designed to identify specific European ancestral subdivisions. They also offer EuropeanDNA, which outlines an individual's fundamental continental European heritage. In forensic science, DNAWitness assists in determining genetic background from crime scene samples, while RETINOME is utilized by detectives to construct physical traits, such as eye color, from DNA evidence or human remains. Furthermore, the company provides the GenomeLab SNPstream Genotyping System, recognized for its high genotyping throughput, multiplexing capabilities, and efficient reagent usage. DNAPrint Genomics caters to diverse clients in fields like forensic investigation, genealogical exploration, consumer products, and pharmaceutical research. Originally incorporated in 1983 as Lexington Energy, Inc., the company operates from Sarasota, Florida, with an international presence through a subsidiary in Leverkusen, Germany.
- ISIN
- US23324Q2021
- Founded
- 1983
- Listed since
- Feb 22, 2001
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.96 | +0.06% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €898.00 | +2.14% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.51 | -0.83% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.